- News & Analysis
- Home
- Latest News
- Reports
- Podcasts
- The CVC Funding Round Database
- The CVC Directory
- University
- Video
- Subscribe
- Newsletters
- Job Postings
- Events
Health
Transcarent takes in $200m
Rush University Medical Center is among the backers of Transcarent’s series C round, which pushed the company’s overall financing to $298m.
Jan 13, 2022Roche rounds up $290m for Freenome
The diagnostics technology developer has raised another $290m from existing investor Roche, which will support it as it looks to expand its products to additional cancers.
Jan 13, 2022Daily Deal Round Up: January 12, 2022
Synthetic DNA producer DNA Script and personalised health plan provider Transcarent each closed $200m corporate-backed series C rounds.
Jan 12, 2022Deals: January 12, 2022
Every day, Global University Venturing rounds up investments from across the university innovation ecosystem in its deal net.
Jan 12, 2022Daily Deal Round Up: January 11, 2022
Business-focused neobank Qonto raised $552m from investors including Tencent at a $552m valuation while SK provided $350m for Center for CDMO Breakthrough Medicines.
Jan 11, 2022Deals: January 11, 2022
Every day, Global University Venturing rounds up investments from across the university innovation ecosystem in its deal net.
Jan 11, 2022Eikon excels at $518m series B
Eikon Therapeutics was co-founded by UC Berkeley researchers, one of whom has already received a Nobel Prize for the underlying technology.
Jan 11, 2022Daily Deal Round Up: January 10, 2022
Raw materials provider Vital Thin Film secured $188m in a round co-led by BYD while drug developers CinCor and Vigil raised a total of $292m in their initial public offerings.
Jan 10, 2022Exits: January 10, 2022
A roundup of exits, including IPOs and acquisitions, across the tech transfer ecosystem.
Jan 10, 2022Deals: January 10, 2022
Every day, Global University Venturing rounds up investments from across the university innovation ecosystem in its deal net.
Jan 10, 2022Korro Bio concludes $116m series B
All existing shareholders including Alexandria Venture Investments contributed to the RNA drug developer’s series B round, following a $91.5m series A in mid-2020.
Jan 10, 2022Featured Content
GCVI Summit 2026 RewindRewatch the sessions, recap the learningsGCVI Summit 2026 Rewind
Rewatch the sessions, recap the learnings
The World of Corporate VenturingGCV's annual report on the state of the corporate investment sectorThe World of Corporate Venturing
GCV's annual report on the state of the corporate investment sector
GCV’s Rising Stars and Emerging Leaders 2026The talent pipeline in corporate venturing shows both momentum and staying power, as the industry comes of age.GCV’s Rising Stars and Emerging Leaders 2026
The talent pipeline in corporate venturing shows both momentum and staying power, as the industry comes of age.
About us
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits our membership, providing privileged access to all our services and resources.
Navigation


